吉西他滨对人胰腺癌SW1990和BxPC3细胞株Notch信号通路的诱导作用

目的 观察吉西他滨对人胰腺癌细胞(SW1990和BxPC3)Notch信号通路活性的影响,探讨其与胰腺癌对吉西他滨化疗耐药的关系.方法 不同浓度吉西他滨处理人胰腺癌SW1990和BxPC3细胞株48 h,实时定量PCR检测Notch信号通路受体Notch1、2、3、4,配体Jagged1、2和下游靶基因Hes1 mRNA的表达,Western blotting测定细胞Hes1蛋白表达.结果 2μmol/L吉西他滨作用胰腺癌细胞株48 h,SW1990细胞的Notch1、2、3、Jagged1、2和Hes1 mRNA表达量分别为8.26±0.48、39.12±4.87、0.84±0.06、105.8±17.92、6.59±0.32和17.30±2.96,均较未处理细胞的1.02±0.15、15.25±1.28、0.12±0.02、32.66±1.98、1.88±0.29和5.02±0.64明显升高(P<0.05或P<0.01);BxPC3细胞上述各项表达量分别为7.87±0.59、109.4±10.98、0.74±0.19、62.73±13.50、2.09±0.16和15.38±1.06,也均较未处理细胞的1.14±0.43、58.96±2.63、0.10±0.02、16.95±3.79、0.98±0.02和2.04±0.16,明显升高(P<0.05或P<0.01).1、2 μmol/L吉西他滨作用胰腺癌细胞株48 h,SW1990细胞Hes1蛋白表达量分别为0.30±0.03、0.42±0.03;BxPC3细胞分别为0.33±0.02、0.45±0.03,均较未处理细胞显著增高(0.13±0.01、F=33.71;0.09±0.02、F=38.54,P值均<0.01).结论 吉西他滨可明显激活SW1990和BxPC3细胞的Notch信号通路,这可能是胰腺癌细胞获得化疗耐受性的机制之一.

Gemcitabine induces Notch signaling pathway activation in pancreatic cancer cell lines SW1990 and BxPC3

Objective To investigate the changes of Notch signaling pathway activity in human pancreatic cancer cell lines (SW1990, BxPC3 )after gemcitabine induction, and to study its relationship with pancreatic cancer resistant to gemcitabine chemotherapy. Methods The pancreatic cancer cell lines SW1990 and BxPC3 were cultured with different concentrations of gemcitabine for 48 hours. The Notch signaling pathway receptors ( Notch1, Notch2, Notch3, Notch4), ligands (Jagged1, Jagged2) and downstream target Hesl mRNAs expression were detected by quantitative real-time PCR (Q-PCR). Protein levels of Hes1 were determined by Western blotting. Results After treatment with 2 μmol/L gemcitabine for 48 hours, the expression of Notch1, Notch2, Notch3, Jagged1, Jagged2 and Hes1 mRNAs in SW1990 cells were 8.26 ±0.48, 39.12 ±4.87, 0.84 ±0.06, 105.8 ± 17.92, 6.59 ±0.32 and 17.30 ±2.96, which were significantly elevated when compared with those without gemcitabine treatment ( 1.02 ± 0. 15, 15.25 ± 1.28, 0. 12 ± 0.02,32.66 ± 1.98, 1.88 ± 0.29 and 5.02 ± 0.64, P < 0.05 or P < 0. 01 ); the expression in BxPC3 cells was 7.87 ±0.59, 109.4 ± 10.98, 0.74 ±0.19, 62.73 ± 13.50, 2.09 ±0.16 and 15.38 ± 1.06, which were significantly elevated when compared with those without gemcitabine treatment ( 1.14 ±0.43, 58.96 ±2.63,0.10 ± 0.02, 16.95 ± 3.79, 0.98 ± 0.02 and 2.04 ± 0.16, P < 0.05 or P < 0.01 ). The expressions of Hes1protein in SW1990 cells after 1, 2 μmol/L gemcitabine treatment for 48 h were 0.30 ±0.03, 0.42 ±0.03;and the expressions in BxPC3 cells were 0.33 ± 0.02, 0.45 ± 0.03, which were significantly increased when compared with those without gemcitabine treatment (0.13 ± 0.01, F = 33.71,0.09 ± 0.02, F = 38.54, P <0.01 ). Conclusions The Notch signaling pathway is significantly activated in pancreatic cancer cells SW1990 and BxPC3 by gemcitabine, which may be one of the mechanisms of chemoresistance.